Aristotle University Of Thessaloniki (AUTH)
Η επίδραση της ενδοφλέβιας χορήγησης σιδήρου στα επίπεδα του αυξητικού παράγοντα των ινοβλαστών 23 του ορού σε παιδιατρικούς ασθενείς με γαστρεντερικό νόσημα
Abstract
dc:descriptionIntroduction: Hypophosphatemia is a known adverse effect of intravenous ferric carboxymaltose (FCM), with the proposed pathophysiological mechanism being an increase in fibroblast growth factor 23 (FGF-23). The biologically active (intact) FGF-23 (iFGF23) increases renal phosphorus (P) excretion and suppresses calcitriol (1,25(OH)₂D) production, leading to further P depletion and secondary hyperparathyroidism. Despite the gradually increasing use of FCM in children, the incidence and pathophysiology of hypophosphatemia in this group remain unclear. This study aimed to investigate the effect of FCM on iFGF23 levels in children with iron deficiency/iron deficiency anemia due to digestive diseases and to identify possible associations between iFGF23 and phosphorus, as well as parameters of phosphorus homeostasis. Method: This is a prospective observational study that lasted 32 months. In 35 children (2-16 years old), who received a total of 43 FCM infusions, iFGF23 was measured at three time points: before FCM infusion (Phase I), 7–10 days (Phase II), and 6–8 weeks (Phase III) after FCM infusion. At the same time, P, calcium (Ca), parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), and alkaline phosphatase (ALP) levels were assessed. Ferritin, total iron binding capacity (TIBC), soluble transferrin receptor (sTfR), C-reactive protein (CRP), hemoglobin (Hb), and erythrocyte indices were also determined. Adverse events were classified according to the Common Criteria for Adverse Events (CTCAE, v 5.0). Statistical analysis was performed using the statistical analysis software package SPSS v29 and graphs were performed with R software v4.2.3. Results: iFGF23 did not show a significant change in the three phases (p = 0.56), nor a linear correlation with the parameters 25(OH)D, PTH, P, Ca, or ALP. However, a marginal increase in Ca was observed in Phase III. Four children (11.42%) experienced transient hypophosphatemia in Phase II, of which 3 were mild (P = 2.05-2.38 mg/dL) and asymptomatic after the first FCM infusion, while one patient with Crohn's disease experienced moderate (P = 1.1 mg/dL) and asymptomatic hypophosphatemia after the third infusion. All cases of hypophosphatemia were self-limited either on day 21 (in 3 patients) or on day 45 (in 1 patient). In these children, iFGF23 levels increased in Phase II compared to patients without hypophosphatemia, even though we did not confirm a statistically significant change. Furthermore, a significant decrease in sTfR and TIBC was observed in our patients (p = 0.01), while Hb and erythrocyte indices increased significantly (p < 0.001). In addition, four patients experienced mild rashes (CTCAE grade I-II, v5.0), and received antihistamines. Conclusions: Although no statistically significant increase in iFGF23 was found after FCM infusion, nor a linear correlation of iFGF23 with P and the examined parameters involved in P homeostasis, an increase in iFGF23 was observed in Phase II in patients with hypophosphatemia, strengthening the hypothesis of its participation in the mechanism of hypophosphatemia. However, the exact role of iFGF23 remains unclear and requires further investigation. In addition, our study confirms the good tolerance and efficacy of FCM in pediatric clinical practice.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntoumpara, Maria
- Ντουμπάρα, Μαρία
Subjects
dc:subject × 16- Σιδηροπενία
- Αναιμία
- Καρβοξυμαλτοζικός σίδηρος
- Αυξητικός παράγοντας ινοβλαστών 23
- Υποφωσφαταιμία
- Iron deficiency
- Anemia
- Ferric carboxymaltose
- Fibroblast growth factor 23
- Hypophosphatemia
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Παιδιατρική, Νεογνολογία και Υγεία του παιδιού
- Clinical Medicine
- Medical and Health Sciences
- Pediatrics, Perinatology and Child Health
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59192